Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 676 to 690 of 729 results for diabet*

  1. Diabetes: annual urinary albumin (children) (IND52)

    This indicator has been updated and replaced by NICE indicator 304 and NICE indicator 305.

    Withdrawn indicator

  2. Diabetes: annual BMI (children) (IND50)

    This indicator has been updated and replaced by NICE indicator 300 and NICE indicator 301.

    Withdrawn indicator

  3. Diabetes: annual blood pressure (children) (IND51)

    This indicator has been updated and replaced by NICE indicator 302 and NICE indicator 303.

    Withdrawn indicator

  4. Diabetes: annual HbA1c (children) (IND49)

    This indicator has been updated and replaced by NICE indicator 298 and NICE indicator 299.

    Withdrawn indicator

  5. Diabetes: annual care processes (children) (IND48)

    This indicator has been updated and replaced by NICE indicator 296 and NICE indicator 297.

    Withdrawn indicator

  6. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

    This guidance has been updated and replaced by NICE technology appraisal guidance 953.

    Withdrawn guidance

  7. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  8. Guidance on the use of long‑acting insulin analogues for the treatment of diabetes – insulin glargine (TA53)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  9. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

    Evidence summary
    Published
    29 January 2013

  10. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (HTG415)

    Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting in adults. This involves reversing blood flow away from the brain and filtering the blood to remove any debris.

    HealthTech guidance
    Published
    22 June 2016
    View recommendations

    Sections for HTG415

  11. Health app: GDm-Health for people with gestational diabetes (MIB131)

    This health app briefing on GDm-Health for people with gestational diabetes has been withdrawn.

    Withdrawn advice

  12. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

    News
    Last updated
    8 December 2025

  13. NICE's prioritisation process explained – what healthtech developers need to know

    Understand why we're prioritising key topic areas for evaluation and what it means for innovators

    News
    Last updated
    4 December 2025

  14. Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS

    Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.

    News
    Last updated
    21 November 2025

  15. Focusing on what matters most to the NHS

    For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.

    News
    Last updated
    4 November 2025